Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12230753 | 0.81 | LMNA (0.43) | CTSLCTSBCTSK | |
| SCHEMBL1514094 | 0.78 | SLC7A5 (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL1514035 | 0.78 | SLC7A5 (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL14872122 | 0.77 | CTSL (0.32) | CTSLCTSBCTSK | |
| SCHEMBL19821996 | 0.76 | CTSL (0.37) | CTSLCTSBCTSK | |
| SCHEMBL15437903 | 0.75 | MGAM (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL685676 | 0.73 | MEN1 (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL26739671 | 0.73 | MMP1 (0.35) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL7965369 | 0.71 | MMP1 (0.34) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL21448749 | 0.71 | MMP1 (0.34) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288146-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-09-25 | — | — | US | disclosed |
| US-8466122-B2 | Trialkyl cationic lipids and methods of use thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288146-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | MMP1 4343/4885MMP2 4043/4885MMP3 3390/4885 |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | MMP1 4343/4885MMP2 4043/4885MMP3 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.